Researchers generated a panel of luminescence-based biosensors which allowed them to elucidate the mechanism of the Pseudomomas aeruginosa siderophore pyochelin (PCH) and its correlation with Ga3+ transport and utilization. Moreover, they have optimized some reactions in the multistep synthesis of Ga3+ carriers and developed novel dry powders for inhalation. Remarkably, all in vivo results clearly prove the possibility of using Ga3+ for inhalation, since they did not observe any toxicity, at least after a single dose and up to 14 days. In addition, the pharmacokinetic results confirm the possibility to reach significant Ga3+ levels in the lung. The research continues with the Extension project (FFC#18/2017) with the aim to explore if Ga3+-derived compounds may represent good candidates to generate broad-spectrum (not only antiPseudomonas, but the other major CF pathogens) antimicrobials and to investigate their toxicology and pharmacokinetics.